Parameters | All patients (n = 177) | 2019 – No-COVID-19 (n = 84) | 2020 – COVID-19 (n = 93) | p-value |
---|---|---|---|---|
Cardiac arrest Characteristics | ||||
Location of IHCA | 0.009 | |||
ICU, n (%) | 83 (47) | 31 (37) | 52 (56) | |
Non-ICU, n (%) | 94 (53) | 53 (63) | 41 (44) | |
Initial rhythm - shockable (VT/VF), n (%) | 42 (24) | 15 (18) | 27 (29) | 0.058 |
Defibrillation, n (%) | 50 (28) | 17 (20) | 33 (35) | 0.018 |
Sustained ROSC, n (%) | 142 (80) | 65 (77) | 77 (83) | 0.237 |
Cardiac re-arrest, n (%) | 53 (30) | 27 (32) | 26 (30) | 0.329 |
Presumed cardiac cause, n (%) | 66 (37) | 35 (42) | 31 (33) | 0.161 |
Epinephrine – total dose, mg, median (IQR) | 2 (1–4) | 2 (1–4) | 2 (1–4) | 0.978 |
Resuscitation time, min; median (IQR) | ||||
No-flow | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.300 |
Total resuscitation time | 5 (2–17) | 4 (1.5–14) | 5 (2–20) | 0.204 |
Targeted temperature management, n (%) | 56 (32) | 27 (32) | 29 (31) | 0.509 |
Use of mechanical compression system, n (%) | 19 (11) | 12 (14) | 7 (8) | 0.114 |
E-CPR, n (%) | 9 (5) | 5 (6) | 4 (4) | 0.436 |
ICU – Characteristics | ||||
Severity of illness | ||||
SAPS II (pts.) median (IQR) | 45 (35–55) | 44 (35–56) | 47 (35–54) | 0.837 |
SOFA – after CA (pts.) median (IQR) | 12 (9–14) | 11 (8–13) | 12 (10–14) | 0.060 |
SOFA – 24 h after CA (pts.) median (IQR) | 11 (7–14) | 11 (7–14) | 11 (8–14) | 0.923 |
Physiological parameters – post CA | ||||
Heart rate – after CA median (IQR) | 96 (77–115) | 94 (77–110) | 96 (77–125) | 0.232 |
MAP – after CA median (IQR) | 73 (63–88) | 76 (62–92) | 72 (63–82) | 0.324 |
Lab values – post CA median (IQR) | ||||
Lactate – highest after CA, mmol/l | 4.5 (1.9–9.1) | 4.8 (2–9.1) | 4.4 (1.9–8.2) | 0.965 |
pH – lowest after CA | 7.26 (7.07–7.36) | 7.26 (7.07–7.34) | 7.26 (7.10–7.36) | 0.755 |
Procedures/Complications – post CA | ||||
Mechanical ventilation, n (%) | 124 (70) | 55 (65) | 69 (74) | 0.031 |
Vasopressor therapy, n (%) | 120 (68) | 49 (58) | 71 (76) | 0.025 |
Renal replacement therapy, n (%) | 26 (15) | 11 (13) | 15 (16) | 0.243 |
Coronary angiography, n (%) | 21 (12) | 14 (17) | 7 (8) | 0.050 |
Hypoxic liver injury, n (%) | 35 (20) | 16 (19) | 19 (20) | 0.484 |
Cholestasis – bilirubin > 2 mg/dl, n (%) | 45 (25) | 22 (26) | 23 (25) | 0.480 |